Logo image of TVTX

TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

USA - NASDAQ:TVTX - US89422G1076 - Common Stock

27.89 USD
+0.57 (+2.09%)
Last: 10/20/2025, 8:19:51 PM
27.75 USD
-0.14 (-0.5%)
After Hours: 10/20/2025, 8:19:51 PM
Fundamental Rating

3

Overall TVTX gets a fundamental rating of 3 out of 10. We evaluated TVTX against 534 industry peers in the Biotechnology industry. TVTX has a bad profitability rating. Also its financial health evaluation is rather negative. TVTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TVTX has reported negative net income.
TVTX had a negative operating cash flow in the past year.
In the past 5 years TVTX always reported negative net income.
In the past 5 years TVTX always reported negative operating cash flow.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

With a decent Return On Assets value of -30.44%, TVTX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
TVTX's Return On Equity of -516.25% is on the low side compared to the rest of the industry. TVTX is outperformed by 78.09% of its industry peers.
Industry RankSector Rank
ROA -30.44%
ROE -516.25%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

The Gross Margin of TVTX (96.89%) is better than 96.25% of its industry peers.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
TVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TVTX has more shares outstanding
Compared to 5 years ago, TVTX has more shares outstanding
Compared to 1 year ago, TVTX has a worse debt to assets ratio.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TVTX has an Altman-Z score of -0.93. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
TVTX has a Altman-Z score (-0.93) which is comparable to the rest of the industry.
A Debt/Equity ratio of 9.50 is on the high side and indicates that TVTX has dependencies on debt financing.
TVTX has a Debt to Equity ratio of 9.50. This is amonst the worse of the industry: TVTX underperforms 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.5
Debt/FCF N/A
Altman-Z -0.93
ROIC/WACCN/A
WACC8.94%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

A Current Ratio of 2.00 indicates that TVTX has no problem at all paying its short term obligations.
TVTX has a worse Current ratio (2.00) than 74.91% of its industry peers.
TVTX has a Quick Ratio of 1.98. This is a normal value and indicates that TVTX is financially healthy and should not expect problems in meeting its short term obligations.
TVTX has a worse Quick ratio (1.98) than 73.60% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.98
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

TVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.11%, which is quite impressive.
Looking at the last year, TVTX shows a very strong growth in Revenue. The Revenue has grown by 87.94%.
Measured over the past years, TVTX shows a small growth in Revenue. The Revenue has been growing by 5.87% on average per year.
EPS 1Y (TTM)58.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.62%
Revenue 1Y (TTM)87.94%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%111.49%

3.2 Future

TVTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.27% yearly.
Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 38.97% on average per year.
EPS Next Y70.96%
EPS Next 2Y43.34%
EPS Next 3Y35.62%
EPS Next 5Y28.27%
Revenue Next Year81.48%
Revenue Next 2Y59.86%
Revenue Next 3Y50.29%
Revenue Next 5Y38.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 124.80 indicates a quite expensive valuation of TVTX.
TVTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. TVTX is cheaper than 86.89% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, TVTX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 124.8
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

TVTX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as TVTX's earnings are expected to grow with 35.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.34%
EPS Next 3Y35.62%

More info and screens

0

5. Dividend

5.1 Amount

TVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (10/20/2025, 8:19:51 PM)

After market: 27.75 -0.14 (-0.5%)

27.89

+0.57 (+2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners116.03%
Inst Owner Change-0.96%
Ins Owners0.83%
Ins Owner Change4%
Market Cap2.49B
Analysts84.76
Price Target37.19 (33.35%)
Short Float %14.36%
Short Ratio5.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.29%
Min EPS beat(2)14.67%
Max EPS beat(2)53.91%
EPS beat(4)2
Avg EPS beat(4)10.07%
Min EPS beat(4)-27.29%
Max EPS beat(4)53.91%
EPS beat(8)3
Avg EPS beat(8)-90.06%
EPS beat(12)5
Avg EPS beat(12)-61.8%
EPS beat(16)5
Avg EPS beat(16)-51.58%
Revenue beat(2)2
Avg Revenue beat(2)8.78%
Min Revenue beat(2)6.09%
Max Revenue beat(2)11.48%
Revenue beat(4)3
Avg Revenue beat(4)4.88%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)11.48%
Revenue beat(8)5
Avg Revenue beat(8)-5.3%
Revenue beat(12)8
Avg Revenue beat(12)-5.78%
Revenue beat(16)9
Avg Revenue beat(16)-10.15%
PT rev (1m)0%
PT rev (3m)6.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.49%
EPS NY rev (1m)-4.12%
EPS NY rev (3m)-7.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.43%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)5.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 124.8
P/S 7.45
P/FCF N/A
P/OCF N/A
P/B 75.92
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)0.22
Fwd EY0.8%
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS3.75
BVpS0.37
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.44%
ROE -516.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.89%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 9.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.47%
Cap/Sales 12.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.98
Altman-Z -0.93
F-Score4
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.62%
EPS Next Y70.96%
EPS Next 2Y43.34%
EPS Next 3Y35.62%
EPS Next 5Y28.27%
Revenue 1Y (TTM)87.94%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%111.49%
Revenue Next Year81.48%
Revenue Next 2Y59.86%
Revenue Next 3Y50.29%
Revenue Next 5Y38.97%
EBIT growth 1Y46.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.04%
EBIT Next 3Y39.42%
EBIT Next 5Y33.79%
FCF growth 1Y45.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.8%
OCF growth 3YN/A
OCF growth 5YN/A